Want a piece of one of Houstons most promising biotech companies? On January 31, FibroBiologics will begin the trading of its common stock on the Nasdaq stock exchange.

While most labs in the realm of regenerative medicine are focused on stem cells, FibroBiologics has bet on fibroblasts as the secret to treating myriad ailments. Fibroblasts, the most common type of cell in the body, are the primary cells that compose connective tissue.

Interested investors can find a prospectus to peruse before taking the leap. FibroBiologics filed with the U.S. Securities & Exchange Commission (SEC) on November 7, 2023. In September, FibroBiologics CEO Pete OHeeron told InnovationMap, I think what we're going to see is that fibroblasts are going to end up winning... They're just a better overall cell than the stem cells.

OHeeron was first exposed to the possibilities of fibroblasts as a means of regrowing discs in the spine. Since starting the company in 2008 as SpinalCyte, OHeeron and FibroBiologics have organically written and filed more than 320 patents. Potential treatments go far beyond spinal surgery to include wound care, cancer, and multiple sclerosis.

According to OHeeron, the goal in going public is to raise capital for human trials.

Weve had really fantastic results with animals and now were ready for humans, he explained in September. We've done small human trials, but we haven't done the large ones that are going to get the commercialization approval from the FDA.

FibroBiologics is growing with impressive speed. OHeeron told us that he is hiring as quickly as he is able to find qualified scientists with the expertise to do the one-of-a-kind work required. The company opened a new lab last fall at the UH Technology Bridge, Newlin-Linscomb Lab for Cell Therapies. With its new status as a publicly traded company, FibroBiologics is primed to break even more ground.

See the article here:
Houston regenerative medicine company to IPO, move toward more human trials - InnovationMap